Net (Loss) Income Per Share (Tables)

9 Months Ended

Jun. 30, 2026

Schedule of Computation of Basic and Diluted Net (Loss) Income Per Share

The following table presents the computation of basic and diluted net (loss) income per share for the three and nine months ended June 30, 2026 and 2025.


	Three Months Ended June 30,				Nine Months Ended June 30,
	2026		2025		2026		2025
	(in thousands, except per share amounts)
Numerator:
Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.	$	(194,280)	$	(175,241)	$	(296,205)	$	22,119

Denominator:
Weighted-average basic shares outstanding (1)	143,378		139,039		141,331		132,385
Effect of dilutive securities	—		—		—		967
Weighted-average diluted shares outstanding (1)	143,378		139,039		141,331		133,352

Basic net (loss) income per share	$	(1.36)	$	(1.26)	$	(2.10)	$	0.17
Diluted net (loss) income per share	$	(1.36)	$	(1.26)	$	(2.10)	$	0.17

(1) Include shares of common stock into which the 2024 and 2026 Avoro Pre-Funded Warrants may be exercised. See Note 6.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table sets forth the number of potentially dilutive securities that have been excluded from the calculation of diluted net (loss) income per share because to include them would be anti-dilutive.


	Three Months Ended June 30,		Nine Months Ended June 30,
	2026	2025	2026	2025
	(in thousands)
Options	830	768	830	756
Restricted stock units	5,795	5,178	5,795	4,770
If-converted common stock from convertible notes	8,039	—	8,039	—
Total	14,664	5,946	14,664	5,526